Production (Stage)
Legend Biotech Corporation
LEGN
$35.00
$3.5211.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 115.04% | 134.56% | 66.60% | 151.27% | 149.90% |
| Total Other Revenue | -97.30% | 446.34% | 1,378.95% | 3,746.03% | 5,844.64% |
| Total Revenue | 107.52% | 134.73% | 66.86% | 154.36% | 158.67% |
| Cost of Revenue | 11.28% | 29.12% | 8.37% | 26.94% | 29.21% |
| Gross Profit | 135.30% | 113.92% | 121.27% | 142.53% | 26.68% |
| SG&A Expenses | 28.99% | 33.25% | 61.72% | 33.01% | 39.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.98% | 30.40% | 22.29% | 28.62% | 31.86% |
| Operating Income | 57.03% | 38.08% | 23.96% | 59.77% | 5.20% |
| Income Before Tax | -65.80% | 127.59% | -93.43% | 90.96% | 46.60% |
| Income Tax Expenses | 35,620.00% | 813.49% | 1,639.93% | -22.07% | -96.09% |
| Earnings from Continuing Operations | -68.78% | 118.15% | -101.46% | 90.86% | 46.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.78% | 118.15% | -101.46% | 90.86% | 46.66% |
| EBIT | 57.03% | 38.08% | 23.96% | 59.77% | 5.20% |
| EBITDA | 57.76% | 39.09% | 24.34% | 61.63% | 5.79% |
| EPS Basic | -67.18% | 118.00% | -99.53% | 91.23% | 51.58% |
| Normalized Basic EPS | -61.38% | 130.38% | -91.54% | 91.33% | 51.45% |
| EPS Diluted | -67.18% | 117.98% | -99.53% | 91.23% | 51.69% |
| Normalized Diluted EPS | -61.38% | 127.65% | -91.54% | 91.33% | 51.45% |
| Average Basic Shares Outstanding | 0.97% | 0.82% | 0.96% | 4.19% | 10.14% |
| Average Diluted Shares Outstanding | 0.97% | 10.77% | 0.96% | 4.19% | 10.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |